Dr. Reddy's Laboratories Ltd Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B), while Roivant Sciences Ltd. Common Shares trades at $33.62 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.3× Dr. Reddy's Laboratories Ltd Common Stock's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dr. Reddy's Laboratories Ltd Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| RDY | ROIV | |
|---|---|---|
Market Cap | $10.78B | $24.99B |
Volume | 2,724,343 | 4,711,562 |
Sector | Health | Health |
52-Week High | $15.38 | $41.81 |
52-Week Low | $11.38 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $10.68B | $21.25B |
Dividend Yield | 0.65% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →